Skip Ribbon Commands
Skip to main content
Sign In

25204 Islet Ag 2 (IA-2) Antibody (IA2)

Islet Ag 2 (IA-2) Antibody (IA2)
Test Code: IA2SO
Synonyms/Keywords
​Iset Cell Antbody, ICA-512, Anti-IA2 Antibodies
Useful For

Clinical distinction of type 1 from type 2 diabetes mellitus

Identification of individuals at risk of type 1 diabetes (including high-risk relatives of patients with diabetes)

Prediction of future need for insulin treatment in adult-onset diabetic patients

Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​1.5 mL ​1.0 mL
Specimen Stability Information
Specimen Type Temperature ​Time
​Serum ​ ​ ​Refrigerate (preferred) ​28 days
​Ambient ​72 hours
​Frozen ​28 days
Rejection Criteria
​Hemolysis​Gross
​Lipemia​Gross
​Icterus​Gross

 

Interference
​Negative results do not exclude the diagnosis of or future risk for type 1 diabetes mellitus. The risk of developing type 1 diabetes may be stratified further by testing for: 1) antibodies targeting insulin, glutamic acid decarboxylase, and zinc transporter 8 (ZnT8) and 2) HLA genetic markers. Careful monitoring of hyperglycemia is the mainstay of determining the requirement for insulin therapy.
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories ​Tuesday and Friday ​3-9 days ​Radioimmunoassay (RIA)
Reference Lab
Test Information

​Islet cell autoantibodies have been known to be associated with type 1 diabetes mellitus for 36 years. In recent years, several autoantigens against which islet antibodies are directed have been identified. These include the tyrosine phosphatase-related islet antigen 2 (IA-2), glutamic acid decarboxylase 65, the zinc transporter ZnT8, and insulin. One or more of these autoantibodies are detected in 96% of patients with type 1 diabetes, and are detectable before clinical onset, as well as in symptomatic individuals. A serological study of 50 type 1 diabetics and 50 control subjects conducted simultaneously across 43 laboratories in 16 countries demonstrated a median sensitivity of 57% and a median specificity of 99% for IA-2 antibody in type 1 diabetes. Prospective studies in relatives of patients with type 1 diabetes have shown that development of 1 or more islet autoantibodies (including IA-2 antibody) provides an early marker of progression to type 1 diabetes. Autoantibody profiles identifying patients destined to develop type 1 diabetes are usually detectable before age 3. In 1 study of relatives seropositive for IA-2 antibody, the risk of developing type 1 diabetes within 5 years was 65.3%. Some patients with type 1 diabetes are initially diagnosed as having type 2 diabetes because of symptom onset in adulthood, societal obesity, and initial insulin-independence. These patients with "latent autoimmune diabetes in adulthood" may be distinguished from those patients with type 2 diabetes by detection of 1 or more islet autoantibodies (including IA-2).

Reference Range Information
Performing Location Reference Range
​Mayo Clinic Laboratories

< or = 0.02 nmol/L

Reference values apply to all ages.

Interpretation
​Seropositivity for IA-2 autoantibody (> 0.02 nmol/L) is supportive of:
-A diagnosis of type 1 diabetes
-A high risk for future development of diabetes
-A current or future need for insulin therapy in patients with diabetes
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​86341
Synonyms/Keywords
​Iset Cell Antbody, ICA-512, Anti-IA2 Antibodies
Ordering Applications
Ordering Application Description
​Centricity ​Islet Antigen 2(IA-2) Antibody (IA2)
​Cerner ​None
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​1.5 mL ​1.0 mL
Specimen Stability Information
Specimen Type Temperature ​Time
​Serum ​ ​ ​Refrigerate (preferred) ​28 days
​Ambient ​72 hours
​Frozen ​28 days
Rejection Criteria
​Hemolysis​Gross
​Lipemia​Gross
​Icterus​Gross

 

Interference
​Negative results do not exclude the diagnosis of or future risk for type 1 diabetes mellitus. The risk of developing type 1 diabetes may be stratified further by testing for: 1) antibodies targeting insulin, glutamic acid decarboxylase, and zinc transporter 8 (ZnT8) and 2) HLA genetic markers. Careful monitoring of hyperglycemia is the mainstay of determining the requirement for insulin therapy.
Useful For

Clinical distinction of type 1 from type 2 diabetes mellitus

Identification of individuals at risk of type 1 diabetes (including high-risk relatives of patients with diabetes)

Prediction of future need for insulin treatment in adult-onset diabetic patients

Reference Range Information
Performing Location Reference Range
​Mayo Clinic Laboratories

< or = 0.02 nmol/L

Reference values apply to all ages.

Interpretation
​Seropositivity for IA-2 autoantibody (> 0.02 nmol/L) is supportive of:
-A diagnosis of type 1 diabetes
-A high risk for future development of diabetes
-A current or future need for insulin therapy in patients with diabetes
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories ​Tuesday and Friday ​3-9 days ​Radioimmunoassay (RIA)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​86341
For most current information refer to the Marshfield Laboratory online reference manual.